We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+19.63%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.55B
AUM Growth
+$1.04B
Cap. Flow
+$118M
Cap. Flow %
1.81%
Top 10 Hldgs %
51.69%
Holding
171
New
48
Increased
43
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$177M
2
BMY icon
Bristol-Myers Squibb
BMY
+$109M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$96.7M
4
INSP icon
Inspire Medical Systems
INSP
+$91.9M
5
COGT icon
Cogent Biosciences
COGT
+$76M

Top Sells

Rank Stock Value
1
OSCR icon
Oscar Health
OSCR
+$250M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$74.9M
3
BAX icon
Baxter International
BAX
+$47.7M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$42.6M
5
UTHR icon
United Therapeutics
UTHR
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.55%
2 Real Estate 0.38%
3 Financials 0.07%
4 Consumer Staples 0.07%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
126
Edwards Lifesciences
EW
$48.3B
$494K 0.01%
+6,349
New +$496K
TMO icon
127
Thermo Fisher Scientific
TMO
$214B
$458K 0.01%
944
+28
+3% +$13K
SHC icon
128
Sotera Health
SHC
$5B
$399K 0.01%
25,384
-19,858
-44% -$279K
XRAY icon
129
Dentsply Sirona
XRAY
$2.68B
$383K 0.01%
+30,183
New +$438K
LH icon
130
Labcorp
LH
$25.5B
$303K ﹤0.01%
+1,057
New +$283K
SCI icon
131
Service Corp International
SCI
$11.8B
$303K ﹤0.01%
+3,635
New +$290K
HSIC icon
132
Henry Schein
HSIC
$9.72B
$278K ﹤0.01%
+4,191
New +$290K
SUPN icon
133
Supernus Pharmaceuticals
SUPN
$2.73B
$255K ﹤0.01%
+5,331
New +$215K
HUM icon
134
Humana
HUM
$46B
$239K ﹤0.01%
917
– –
OGN icon
135
Organon & Co
OGN
$3.56B
$175K ﹤0.01%
16,388
– –
TOIIW
136
The Oncology Institute Warrant
TOIIW
$4.45M
$150K ﹤0.01%
1,250,000
– –
TNDM icon
137
Tandem Diabetes Care
TNDM
$1.22B
$148K ﹤0.01%
+12,195
New +$165K
CYH icon
138
Community Health Systems
CYH
$393M
$105K ﹤0.01%
32,720
-22,983
-41% -$69K
QSIAW
139
DELISTED
Quantum-Si Inc Warrant
QSIAW
$90K ﹤0.01%
333,333
– –
NUVB.WS
140
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$33.7K ﹤0.01%
166,666
– –
BFLY.WS
141
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$33.4K ﹤0.01%
733,333
– –
EBS icon
142
Emergent Biosolutions
EBS
$376M
$16.5K ﹤0.01%
1,872
– –
PMVP icon
143
PMV Pharmaceuticals
PMVP
$59.7M
$12.3K ﹤0.01%
8,790
– –
MYGN icon
144
Myriad Genetics
MYGN
$501M
$3.65K ﹤0.01%
505
– –
SRZNW icon
145
Surrozen Inc Warrant
SRZNW
$75.6K
$2.97K ﹤0.01%
166,666
– –
AMED
146
DELISTED
Amedisys
AMED
– –
-2,744
Closed -$270K
AMPH icon
147
Amphastar Pharmaceuticals
AMPH
$879M
– –
-9,579
Closed -$220K
CRL icon
148
Charles River Laboratories
CRL
$11.4B
– –
-43
Closed -$6.52K
DCTH icon
149
Delcath Systems
DCTH
$404M
– –
-812,561
Closed -$11.1M
HLVX
150
DELISTED
HilleVax
HLVX
– –
-1,882,654
Closed -$3.75M
3 4 5
6
7

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2025 Portfolio in Review

As of Q3 2025, Deerfield Management held 171 positions worth $6.55B, up 19% from $5.51B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q3 2025 filing shows 48 new, 43 increased, 20 reduced and 19 closed positions. Its largest new stake was Bristol-Myers Squibb: 2,337,771 shares worth $105M. The largest sale was Oscar Health, an estimated $250M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier, followed by Real Estate and Financials.

  • Deerfield Management's largest Q3 2025 buy was Bristol-Myers Squibb: 2,337,771 shares worth $105M.
  • Deerfield Management added most to Centene in Q3 2025, an estimated $177M increase.
  • Deerfield Management's biggest Q3 2025 reduction was Indivior Pharmaceuticals, cutting an estimated $74.9M.
  • Deerfield Management fully exited Oscar Health in Q3 2025, selling an estimated $250M.
  • Deerfield Management's ten largest holdings make up 52% of its $6.55B portfolio in Q3 2025.
  • Deerfield Management opened 48 new positions and closed 19 in Q3 2025.
  • Deerfield Management's portfolio value rose 19% quarter-over-quarter to $6.55B.

Based on Deerfield Management's 13F filing for Q3 2025, filed 14 Nov 2025.